Sei Investments Co. Decreases Stock Holdings in InMode Ltd. (NASDAQ:INMD)

Sei Investments Co. cut its stake in InMode Ltd. (NASDAQ:INMD) by 17.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 36,605 shares of the healthcare company’s stock after selling 7,711 shares during the period. Sei Investments Co. owned approximately 0.05% of InMode worth $611,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in shares of InMode during the 4th quarter worth $87,000. Farther Finance Advisors LLC boosted its position in shares of InMode by 26.2% during the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company’s stock worth $93,000 after purchasing an additional 1,154 shares during the period. National Bank of Canada FI grew its stake in shares of InMode by 6.2% in the third quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company’s stock valued at $169,000 after buying an additional 579 shares in the last quarter. HighTower Advisors LLC acquired a new position in InMode in the 4th quarter valued at about $180,000. Finally, DGS Capital Management LLC acquired a new stake in shares of InMode during the third quarter worth about $182,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Stock Performance

Shares of NASDAQ INMD opened at $15.46 on Thursday. The stock’s 50-day simple moving average is $18.11 and its 200-day simple moving average is $17.70. The firm has a market capitalization of $1.08 billion, a PE ratio of 6.58 and a beta of 1.96. InMode Ltd. has a fifty-two week low of $14.22 and a fifty-two week high of $19.85.

Analysts Set New Price Targets

INMD has been the subject of a number of analyst reports. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research report on Wednesday. Barclays boosted their price target on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $22.25.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.